Based on these findings, a phase II clinical trial was initiated with the goal to determine the efficacy of ex vivo HSP70 peptide plus IL-2 stimulated autologous NK cells in patients with inoperable non-small cell lung cancer (NSCLC) in stage IIIA/B after radiochemotherapy [38,39]. Here, IL2 is linked to non-small cell lung carcinoma.